“The first quarter of 2024 was transformational for Q32 as we became a public company and continued to drive the advancement of our pipeline programs. Bempikibart is progressing in the ongoing Phase 2 clinical trials in AD and AA, with topline data from each expected to be released in the fourth quarter of 2024,” said Jodie Morrison, Chief Executive Officer of Q32 Bio. “We are pleased with the progress we are making in both of these Phase 2 trials, including completing AA enrollment.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTTB:
- Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Q32 Bio files to sell 1.68M shares of common stock for holders
- Oppenheimer starts Q32 Bio with Outperform, sees 150% potential upside
- Q32 Bio initiated with an Outperform at Oppenheimer
- Q32 Bio names Lee Kalowski as CFO
Questions or Comments about the article? Write to editor@tipranks.com